<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:chebi fb="0" ids="6801">Metformin</z:chebi>, the major target of which is liver, is commonly used to treat type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Although <z:chebi fb="0" ids="6801">metformin</z:chebi> activates <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase (AMPK) in hepatocytes, the mechanism of activation is still not well known </plain></SENT>
<SENT sid="2" pm="."><plain>To investigate AMPK activation by <z:chebi fb="0" ids="6801">metformin</z:chebi> in liver, we examined the role of reactive nitrogen species (<z:chebi fb="0" ids="33697">RNS</z:chebi>) in suppression of hepatic gluconeogenesis </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: To determine <z:chebi fb="0" ids="33697">RNS</z:chebi>, we performed fluorescence examination and immunocytochemical staining in mouse hepatocytes </plain></SENT>
<SENT sid="4" pm="."><plain>Since <z:chebi fb="0" ids="6801">metformin</z:chebi> is a mild <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> complex I inhibitor, we compared its effects on suppression of gluconeogenesis, AMPK activation and generation of the <z:chebi fb="0" ids="33697">RNS</z:chebi> <z:chebi fb="0" ids="25941">peroxynitrite</z:chebi> (<z:chebi fb="0" ids="29330">ONOO</z:chebi>(-)) with those of <z:chebi fb="0" ids="28201">rotenone</z:chebi>, a representative complex I inhibitor </plain></SENT>
<SENT sid="5" pm="."><plain>To determine whether endogenous nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> production is required for <z:chebi fb="0" ids="29330">ONOO</z:chebi>(-) generation and <z:chebi fb="0" ids="6801">metformin</z:chebi> action, we used mice lacking endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (eNOS) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> and <z:chebi fb="0" ids="28201">rotenone</z:chebi> significantly decreased gluconeogenesis and increased phosphorylation of AMPK in <z:mp ids='MP_0002169'>wild-type</z:mp> mouse hepatocytes </plain></SENT>
<SENT sid="7" pm="."><plain>However, unlike <z:chebi fb="0" ids="28201">rotenone</z:chebi>, <z:chebi fb="0" ids="6801">metformin</z:chebi> did not increase the <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>/ATP ratio </plain></SENT>
<SENT sid="8" pm="."><plain>It did, however, increase <z:chebi fb="0" ids="29330">ONOO</z:chebi>(-) generation, whereas <z:chebi fb="0" ids="28201">rotenone</z:chebi> did not </plain></SENT>
<SENT sid="9" pm="."><plain>Exposure of eNOS-deficient hepatocytes to <z:chebi fb="0" ids="6801">metformin</z:chebi> did not suppress gluconeogenesis, activate AMPK or increase <z:chebi fb="0" ids="29330">ONOO</z:chebi>(-) generation </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, <z:chebi fb="0" ids="6801">metformin</z:chebi> lowered fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels in <z:mp ids='MP_0002169'>wild-type</z:mp> diabetic mice, but not in eNOS-deficient diabetic mice </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS/INTERPRETATION: Activation of AMPK by <z:chebi fb="0" ids="6801">metformin</z:chebi> is dependent on <z:chebi fb="0" ids="29330">ONOO</z:chebi>(-) </plain></SENT>
<SENT sid="12" pm="."><plain>For <z:chebi fb="0" ids="6801">metformin</z:chebi> action in liver, intra-hepatocellular eNOS is required </plain></SENT>
</text></document>